Kyowa Kirin Releases Phase III Results On Parkinson’s Drug
This article was originally published in PharmAsia News
Executive Summary
Kyowa Kirin announced on June 19 that results of Phase III trials of KW-6002 for use in treating Parkinson’s disease were reported at the International Congress of Parkinson’s Disease and Movement Disorders held in Dublin.